- Home
- ECBK vs LCTX Comparison
ECBK vs LCTX Comparison
Compare ECBK & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECBK
- LCTX
- Stock Information
- Founded
- ECBK 1919
- LCTX 1990
- Country
- ECBK United States
- LCTX United States
- Employees
- ECBK N/A
- LCTX N/A
- Industry
- ECBK Banks
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ECBK Finance
- LCTX Health Care
- Exchange
- ECBK Nasdaq
- LCTX Nasdaq
- Market Cap
- ECBK 134.8M
- LCTX 110.2M
- IPO Year
- ECBK N/A
- LCTX N/A
- Fundamental
- Price
- ECBK $14.86
- LCTX $0.53
- Analyst Decision
- ECBK
- LCTX Strong Buy
- Analyst Count
- ECBK 0
- LCTX 4
- Target Price
- ECBK N/A
- LCTX $5.25
- AVG Volume (30 Days)
- ECBK 7.1K
- LCTX 4.2M
- Earning Date
- ECBK 10-24-2024
- LCTX 11-14-2024
- Dividend Yield
- ECBK N/A
- LCTX N/A
- EPS Growth
- ECBK N/A
- LCTX N/A
- EPS
- ECBK 0.39
- LCTX N/A
- Revenue
- ECBK $24,711,000.00
- LCTX $8,719,000.00
- Revenue This Year
- ECBK N/A
- LCTX N/A
- Revenue Next Year
- ECBK N/A
- LCTX $123.52
- P/E Ratio
- ECBK $39.36
- LCTX N/A
- Revenue Growth
- ECBK N/A
- LCTX N/A
- 52 Week Low
- ECBK $11.39
- LCTX $0.48
- 52 Week High
- ECBK $15.75
- LCTX $1.61
- Technical
- Relative Strength Index (RSI)
- ECBK 44.96
- LCTX 38.21
- Support Level
- ECBK $14.98
- LCTX $0.48
- Resistance Level
- ECBK $15.37
- LCTX $0.61
- Average True Range (ATR)
- ECBK 0.28
- LCTX 0.05
- MACD
- ECBK -0.03
- LCTX 0.00
- Stochastic Oscillator
- ECBK 5.32
- LCTX 38.93
About ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.